Trends in Industry Marketing of Stimulants to Physicians and Advanced Practice Clinicians.
作者信息
Donahoe J Travis, Wilson Linnea M, Anderson Timothy S
机构信息
Department of Health Policy and Management, University of Pittsburgh School of Public Health, Pennsylvania.
Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
出版信息
JAMA Pediatr. 2025 Aug 25. doi: 10.1001/jamapediatrics.2025.2811.
Abstract
摘要
相似文献
1
Trends in Industry Marketing of Stimulants to Physicians and Advanced Practice Clinicians.
JAMA Pediatr. 2025 Aug 25. doi: 10.1001/jamapediatrics.2025.2811.
2
Interactions between non-physician clinicians and industry: a systematic review.
PLoS Med. 2013 Nov;10(11):e1001561. doi: 10.1371/journal.pmed.1001561. Epub 2013 Nov 26.
4
From hyper- to hypo-: ADHD medications & sexual dysfunction.
J Sex Med. 2025 May 10;22(5):701-710. doi: 10.1093/jsxmed/qdaf054.
5
Recent Trends in Medication Treatment for Attention-Deficit Hyperactivity Disorder.
Psychiatr Serv. 2025 May 28:appips20240574. doi: 10.1176/appi.ps.20240574.
6
United States trends in non-prescribed use of Adderall and Ritalin: Population Assessment of Tobacco and Health (PATH) Study estimates from 2013 to 2022.
Addiction. 2025 Jul 2. doi: 10.1111/add.70123.
7
Cannabis Use in a Community-Based Sample of Adults Diagnosed With ADHD: Prevalence, Impact on Symptoms, and Stimulant Side Effects.
J Atten Disord. 2025 Aug 28:10870547251364575. doi: 10.1177/10870547251364575.
8
Associations of hepatitis C virus (HCV) antibody positivity with opioid, stimulant, and polysubstance injection among people who inject drugs (PWID) in rural U.S. communities.
Int J Drug Policy. 2023 Oct 6:104222. doi: 10.1016/j.drugpo.2023.104222.
9
Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
J Am Acad Child Adolesc Psychiatry. 2008 Jan;47(1):21-31. doi: 10.1097/chi.0b013e31815a56f1.
10
Trends in Nonfatal Fentanyl Exposures Involving Stimulants in the United States, 2015-2023.
Am J Prev Med. 2025 Jun 9;69(3):107742. doi: 10.1016/j.amepre.2025.107742.
本文引用的文献
1
High-Risk Opioid Prescribing and Nurse Practitioner Independence.
JAMA Health Forum. 2024 Dec 6;5(12):e244544. doi: 10.1001/jamahealthforum.2024.4544.
2
Stimulant, Antidepressant, and Opioid Telehealth Prescription Trends Between 2019 and 2022.
JAMA Netw Open. 2024 Sep 3;7(9):e2433334. doi: 10.1001/jamanetworkopen.2024.33334.
3
Stimulant misuse among youth.
Curr Probl Pediatr Adolesc Health Care. 2022 Sep;52(9):101265. doi: 10.1016/j.cppeds.2022.101265. Epub 2022 Sep 29.
4
Are Financial Payments From the Pharmaceutical Industry Associated With Physician Prescribing? : A Systematic Review.
Ann Intern Med. 2021 Mar;174(3):353-361. doi: 10.7326/M20-5665. Epub 2020 Nov 24.
5
Analysis of Pharmaceutical Industry Marketing of Stimulants, 2014 Through 2018.
JAMA Pediatr. 2020 Apr 1;174(4):385-387. doi: 10.1001/jamapediatrics.2019.5526.
Zotero 插件